(Q37920966)

25 August 2017

1 reference

title

Immune alterations in untreated and treated multiple myeloma (English)

1 reference

25 August 2017

Constantin A Dasanu

1

1 reference

25 August 2017

publication date

22 August 2011

1 reference

Journal of Oncology Pharmacy Practice

25 August 2017

published in

1 reference

25 August 2017

volume

18

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

257-263

1 reference

Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

[Secondary malignant neoplasms in patients with breast cancer]

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Immunodeficiency and immunotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

High Th1/Th2 ratio in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Th1/Th2 cells in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Regulatory T cells and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Mutations in GNA11 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Associations between ocular melanoma and other primary cancers: an international population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211412842

21 January 2018

Identifiers

DOI

10.1177/1078155211412842

1 reference

25 August 2017

1 reference